^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CCT244747

    i
    Other names: CCT244747
    Associations

    News

    Trials
    Company:
    Sareum
    Drug class:
    Chk1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway. (PubMed, Biochem J)
    Total and phospho proteomic analysis revealed that Eµ-Myc/cRel-/- lymphomas highly resemble wild-type (WT) Eµ-Myc lymphomas treated with an acute dose of the CHK1 inhibitor (CHK1i) CCT244747...We demonstrate that treating WT Eµ-Myc lymphoma cells with the USP1 inhibitor ML323 was highly effective at reducing tumour burden in vivo. Targeting USP1 activity may thus be an alternative therapeutic strategy in MYC-driven tumours.
    Journal
    |
    USP1 (Ubiquitin Specific Peptidase 1)
    |
    CCT244747